N+1 Singer reported on Vernalis PLC (LON:VER), keeping its stock price target at 46.00GBX earlier today
- Updated: September 28, 2016
N+1 Singer hold steady the price target of Vernalis PLC (LON:VER) at 46.00GBX reporting a possible upside of 0.13%.
On 9/22/2016, Panmure Gordon released a statement about Vernalis PLC (LON:VER) maintained the target price at 76.00GBX that suggested an upside of 0.71%.
Having a price of 40.88GBX, Vernalis PLC (LON:VER) traded -8.15% lower on the day. With the last stock price down -10.70% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. VER has recorded a 50-day average of 43.85GBX and a two hundred day average of 45.78GBX. Trade Volume was up over the average, with 308,767 shares of VER changing hands over the typical 293,413
Recent Performance Chart
Vernalis PLC has with a one year low of 31.00GBX and a one year high of 79.00GBX and has a market capitalization of 0 GBX.
A total of 5 brokerages have issued a ratings update on Vernalis PLC. Two brokerages rating the company a strong buy, two brokerages rating the company a buy, one brokerage rating the company a hold, zero brokerages rating the company a underperform, and finally zero brokerages rating the company a sell with a 12-month price target of 83.60GBX.
General Company Details For Vernalis PLC (LON:VER)
Vernalis plc is a commercial-stage pharmaceutical holding company. The Company is engaged in the research, development and commercialization of pharmaceutical products for a range of medical disorders. The Company has two marketed products: Tuzistra XR in the United States prescription cough cold market, and frovatriptan, an acute treatment for migraine. The Company also has four prescription cough cold products under development, and a pipeline of research and new chemical entity (NCE) development programs. Its commercial pipeline candidates include CCP-05, CCP-06, CCP-07 and CCP-08. The Company operates in the United Kingdom, Rest of Europe, North America and Rest of the World. The Company is also engaged in fragment- and structure-based drug discovery. It has two development products in the central nervous system (CNS) therapeutic area: the fatty acid amide hydrolase (FAAH) inhibitor V158866 for pain, and V81444, an adenosine A2A receptor antagonist as a treatment for CNS diseases.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.